Back to Conference page
UICC World Cancer Congress 2006
Bridging the Gap: Transforming Knowledge into Action
July 8-12, 2006, Washington, DC, USA
Methods:The 1137 eligible women from Nanshan District, Shenzhen city were investigated between 2004.11-2004.12. The high risk type HPV of cervical cell samples were tested by hc2 and Yaneng gene chips technology in double blind at the same time. AutoCyte Liquid-based cytology tests (LCT) were also performed. Women for LCT>=LSIL or LCT>=ASCUS with HPV-positive were biopsy in colposcopy and then were examined by pathology. The pathology results were gold standard to evaluate the gene chips technology.
Results:HPV-positive rates in this population were 14.0% by hc2 and 9.8% by Yaneng gene chips. The HPV-positive rate by hc2 was higher than that of Yaneng gene chips (P<0.001). The sensitivity, specificity, accuracy, positive prevalue, negative prevalue of hc2 HPV for >=CIN II were 100%, 87.1%, 87.3%, 8.8 and 100%, respectively; Those of Yaneng gene chips were 78.6%, 91.1%, 90.9%, 9.9% and 99.7%, respectively.
Conclusions: It is suggested that hc2 high risk HPV testing is still the best method for cervical cancer screening at present. Except that the sensitivity of Yaneng gene chips HPV testing for cervical high grade lesions need be improved, the others of Yaneng gene chips HPV are compare beauty with hc2.